Should I use antiviral therapy for chronic hepatitis B?
References
Citations
Lok ASF, McMahon BJ (2007). Chronic hepatitis B. Hepatology, 45(2): 507–539.
Marcellin P, et al. (2004). Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAG-negative chronic hepatitis B. New England Journal of Medicine, 351(12): 1206–1217.
Lau GKK, et al. (2005). Peginterferon alfa-2a, lamivudine, and the combination for HBeAG-positive chronic hepatitis B. New England Journal of Medicine, 352(26): 2682–2695.
Hadziyannis SJ, et al. (2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine, 348(9): 800–807.
Marcellin P, et al. (2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine, 389(9): 808–816
Lai CL, et al. (2002) Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 123(6): 2135–2140.
de Man RA, et. al. (2001) Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology, 34(3): 578–82.
Lai C-L, et al. (2007). Telbivudine versus lamivudine in patients with chronic hepatitis B. New England Journal of Medicine, 357(25): 2576–2588.
| Author: | Maria G. Essig, MS, ELS | Last Updated: October 15, 2007 |
| Medical Review: | Kathleen Romito, MD - Family Medicine W. Thomas London, MD - Hepatology | |
 | ||
| |